同仁堂国药子公司获澳门6款中成药注册证明书，公司明示对当前业绩无重大影响

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take
no responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
in reliance upon the whole or any part of the contents of this announcement.

BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
北京同仁堂國藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3613)

VOLUNTARY ANNOUNCEMENT
RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY
CHINESE MEDICINE
This announcement is made by the board of directors (the “Board”) of Beijing Tong Ren Tang
Chinese Medicine Company Limited (the “Company”) on a voluntary basis to inform its
shareholders and potential investors of the latest business development about the Company.
The Board is pleased to announce that the subsidiary of the Company, Beijing Tong Ren Tang
(Macau) Company Limited (“TRT Macau”), received the Certificate of Registration of Proprietary
Chinese Medicine (《 中 成 藥 註 冊 證 明 書 》 ) issued by the Pharmaceutical Administration
Bureau of Macao Special Administrative Region Government, allowing “Shilintong Keli【Tong
Ren Tang】” (石淋通顆粒【同仁堂】), “Shugan Jianwei Wan【Tong Ren Tang】” (舒肝健胃丸
【同仁堂】), “Sishen Wan【Tong Ren Tang】” (四神丸【同仁堂】), “Huangjing Wan【Tong
Ren Tang】” (黃精丸【同仁堂】), “Zibu Jianshen Wan 【Tong Ren Tang】” (滋補健身丸【同仁
堂】) and “Zhuangyuan Wan【Tong Ren Tang】” (狀元丸【同仁堂】) (collectively named as
“Medicines”) to be sold in the Macao Special Administrative Region of the People’s Republic of
China (“Macao”). The relevant details are as follows:

–1–

No.

Name of medicines

Registration number

1

Shilintong Keli【Tong Ren
Tang】(石淋通顆粒【同仁
堂】)

MAC-C00365

2

Shugan Jianwei Wan【Tong
Ren Tang】(舒肝健胃丸【同
仁堂】)

MAC-C00448

3

Sishen Wan【Tong Ren
Tang】(四神丸【同仁堂】)

MAC-C00457

4

Huangjing Wan【Tong Ren
Tang】(黃精丸【同仁堂】)

MAC-C00537

5

Zibu Jianshen Wan【Tong
Ren Tang】(滋補健身丸【同
仁堂】)

MAC-C00594

–2–

Function and main indications
To clear dampness-heat, promote
urination and expel stone. Indicated
for urinary stone, pyelonephritis
and cholecystitis.
To soothe the liver, resolve
depression, remove stagnation and
harmonise the middle. Indicated for
distending pain in the epigastrium,
fullness and oppression in the
chest, vomiting, acid regurgitation,
abdominal distension and
constipation due to liver-stomach
disharmony.
To warm the kidney and disperse
cold, astringe the intestine and stop
diarrhoea. Indicated for diarrhoea
due to deficiency of kidney yang,
manifested as borborygmus,
abdominal distension, diarrhoea
before dawn, reduced food intake,
undigested food in the stool,
protracted diarrhoea, sallow
complexion, and cold limbs.
To tonify qi and nourish blood.
Indicated for deficiency of qi and
blood, physical weakness, lack of
strength in the lower back and legs,
lassitude and reduced food intake.
To tonify the kidney, regulate the
spleen, eliminate dampness and
relieve distension. Indicated for
fatigue, soreness and weakness in
the lower back and knees, and
heavy limbs due to spleen-stomach
weakness.

No.

6

Name of medicines

Zhuangyuan Wan【Tong Ren
Tang】(狀元丸【同仁堂】)

Registration number

Function and main indications

MAC-C00621

To nourish the heart, enrich the
kidney, invigorate the brain and
tranquilise the mind. Indicated for
insomnia, forgetfulness, deficiency
vexation, dream-disturbed sleep,
palpitations, restlessness, dim
vision, tinnitus, fatigue due to
heart-kidney deficiency and brain
overexertion.

The registrant of the Medicines is TRT Macau. As of the date of this announcement, the relevant
registration fee of the Medicines incurred by the Company is approximately HK$50,000 (unaudited).
The Medicines have not yet been launched for sale in Macao.
Impact on the Company and Risk Warning
Upon obtaining the Certificate of Registration of Proprietary Chinese Medicine issued by the
Pharmaceutical Administration Bureau of Macao Special Administrative Region Government, the
Medicines can be sold in Macao, which is beneficial to its market expansion. The obtaining of the
aforementioned certificate of registration will not have any material impact on the production,
operation and performance of the Company for the time being. The sales of pharmaceutical products
can be influenced by factors such as changes in the policy environment, exchange rate fluctuations
and market competition in the Macao region.
Shareholders and potential investors should exercise caution when dealing in the securities of
the Company.
By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Yan Han
Chairman

Hong Kong, 14 October 2026

As at the date of this announcement, the composition of the Board is as follows:
Executive Directors:
Mr. Yan Han (Chairman)
Mr. Yue Zheng (Vice Chairman)
Mr. Wang Chi

Independent Non-executive Directors:
Mr. Tsang Yok Sing, Jasper
Mr. Xu Hong Xi
Mr. Chan Ngai Chi

Non-executive Director:
Ms. Feng Li
–3–